Peptide

PEG-IGF-1

Also known as

Pegylated IGF-1 · PEG-IGF-I · PEGylated IGF-I · PEG IGF-1 · PEG-IGF1 · Pegylated recombinant human IGF-1 · PEGylated recombinant human insulin-like growth factor-I · RO5046013 (Roche clinical-research designation) · PEG-rhIGF-I · Long-acting IGF-1 (loose forum shorthand — not LR3)

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

PEG-modified growth factor	PEG-IGF-1 attaches polyethylene glycol to IGF-1 to prolong exposure. People discuss muscle-growth and recovery signaling, but longer acting does not mean muscle-selective.
Identity confusion	PEG-IGF-1, PEG-MGF, LR3 and DES are different identities. A gym vial cannot be assumed to match the pharmaceutical PEG-IGF-I construct RO5046013.

Notes

PEG-IGF-1 is insulin-like growth factor 1 modified with polyethylene glycol to prolong exposure. People discuss it for longer-lasting muscle-growth and recovery signaling, but “PEG IGF” posts often describe PEG-MGF or LR3 instead; a familiar name or pump does not confirm the product.

PEG changes how the growth factor behaves. Attaching polyethylene glycol can slow removal and alter receptor and binding-protein interactions. IGF signaling affects many tissues, so “longer acting” does not mean muscle-selective. Metzger et al.: site-specific PEGylation of IGF-I (Official context · Accessed 2026-09-30)

PEG-IGF-1, PEG-MGF and LR3 are separate identities. PEG-MGF is the MGF-related peptide discussed for repair; LR3 and DES are different IGF analogues. HGH and GH-releasing compounds act upstream. A vial labeled PEG-IGF cannot be assumed to match the pharmaceutical RO5046013 studied in humans.

Source context — Metzger et al.: site-specific PEGylation of IGF-I: PubMed recaptcha; PMC changed to recaptcha during follow-up. Used API abstract only; cell/animal work does not establish human benefit or all possible PEG chemistries.

What people notice

What people seek	Longer coverage, fewer injections, fullness and smoother recovery draw interest. The saved impressions lack a verified, timed PEG-IGF-only log.
Claims involving other compounds	One favorable PEG-IGF mention also involved PEG-MGF, without a solo follow-up. Other recovery praise or disappointment in nearby threads concerns PEG-MGF rather than PEG-IGF-1.

Notes

Longer coverage and fewer injections. That is the attraction in the community account, alongside smoother recovery, muscle fullness and retaining size through hard training or cuts. These are discussion claims; stacks, diet and training make single-compound credit difficult.

A reliable first-dose onset is unknown. The community record describes no stimulant-like rush, possible site awareness, and mild fullness or recovery impressions during days 1–7. Those impressions lack a timed, verified PEG-IGF-only log.

Stamina and strength are claimed in a combination. An Eroids participant favored PEG-IGF with PEG-MGF and described post-workout use; increased stamina/strength before training was a prediction, without an isolated outcome log. Interested in IGF1LR3: the PEG-IGF/PEG-MGF reply (Community discussion · Accessed 2026-09-30)

The positive PEG-IGF mention lacks a solo follow-up. HydeMind's combination appraisal is worth retaining, but its workout timing does not establish when PEG-IGF starts or stops working. Interested in IGF1LR3: the PEG-IGF/PEG-MGF reply (Community discussion · Accessed 2026-09-30)

Recovery praise and disappointment often concern PEG-MGF. In SteroidFreaks, one participant recalled little benefit from PEG-MGF/IGF; another praised PEG-MGF recovery while doubting new tissue growth. Neither reported PEG-IGF-1. Thoughts on PEG MGF and IGF-1 LR3 Cycling (Community discussion · Accessed 2026-09-30)

Source context — Interested in IGF1LR3: the PEG-IGF/PEG-MGF reply: HydeMind names PEG-IGF with PEG-MGF and post-workout use but gives no dose, route, identity assay or timed follow-up. Positive appraisal and pre-workout prediction are not isolated PEG-IGF outcomes. Other participants' amounts and appetite/pump reports concern LR3 or unspecified IGF.

Source context — Thoughts on PEG MGF and IGF-1 LR3 Cycling: PEG refers to PEG-MGF; results are comparison context, not PEG-IGF-1 outcomes. Retrospective accounts, unverified products, no controlled exposure. Storage and pharmaceutical-grade claims not verified or adopted.

Doses people talk about

PEG-IGF-1 amount	No stable construct-specific community dose with a matched amount, route and frequency is established. Weekly or few-times-weekly use remains an intermittent-use idea.
Borrowed IGF/LR3 charts	20–50 or 20–100 mcg are comparison bands, with no established per-injection versus daily meaning for a PEG product. They are not verified PEG-IGF-1 amounts.
PEG-MGF is separate	100–400 mcg, 2–3 times weekly belongs to PEG-MGF comparison talk; neither amount nor frequency supplies a PEG-IGF-1 schedule.

Notes

No established PEG-IGF-1 community amount. The retained discussion has no stable construct-specific dose. Weekly or a few-times-weekly exposure is an intermittent-use idea, without a consistent matched amount, route and frequency.

20–50 or 20–100 mcg are borrowed IGF/LR3 comparisons. These overlapping chart bands are not verified PEG-IGF-1 amounts. The original does not establish whether they mean per injection or daily total for a PEG product; LR3's 5–7-times-weekly habit cannot resolve that gap.

100–400 mcg, 2–3 times weekly refers to PEG-MGF. That separate chart comparison stays separate from PEG-IGF-1. Neither its amount nor its frequency supplies a PEG-IGF schedule.

Half-life, onset & duration

Felt onset	Mild fullness or recovery impressions during days 1–7 and later workout checkpoints lack a verified PEG-IGF-only timeline. A reliable first-dose onset is unknown.
Felt duration	Single-dose benefit and offset are unknown. Multi-day circulation lore and weeks-long runs do not time a fullness or recovery feeling.
Half-life	A human pharmaceutical RO5046013 study reported 140–200 hours after single SubQ dosing or a 48-hour IV infusion, without splitting values by route. It does not establish a gym vial's half-life.

Notes

Weeks 1–2 and 3–4 are observation windows. The original mentions checking pumps and recovery in the first two weeks and possible physique impressions around weeks 3–4. These are loosely attributed checkpoints, not demonstrated onset times or promised changes.

Single-dose felt duration and offset are unknown. Multi-day circulation lore does not tell us how long a workout, fullness or recovery feeling lasts. The original's weeks 4–8 discussion describes extended runs; it does not measure one injection's effects.

Stopping is not a proven washout date. Residual-exposure discussion and post-stop impressions remain uncertain. Ongoing training and other compounds prevent a clean attribution of effects after the last reported administration.

Multi-day exposure is discussed; a community measurement is missing. AnabolicMinds debated whether days of systemic PEG-IGF activity were desirable. This was opinion about exposure, not a measured human half-life. peg mgf: discussion of a hypothetical PEG-IGF (Community discussion · Accessed 2026-09-30)

140–200 hours: pharmaceutical RO5046013. The 62-volunteer study used single SubQ administration or a 48-hour IV infusion; its abstract does not split half-life by route. No hypoglycemia occurred, and SubQ redness was the most frequent adverse event. The comparator was unmodified rhIGF-I. These findings do not establish a gym dose or felt duration. Kletzl et al.: first-in-man RO5046013 study (Official context · Accessed 2026-09-30)

Source context — peg mgf: discussion of a hypothetical PEG-IGF: Discussion largely concerns PEG-MGF. PEG-IGF comments are opinion about systemic exposure, not a measured half-life or firsthand organ-growth case. One poster is labeled Board Sponsor. Preparation/injection advice and jokes excluded.

Source context — Kletzl et al.: first-in-man RO5046013 study: PubMed gave a disclosure-only page; ScienceDirect opens failed. Search-result section snippets not treated as inspected full text. API abstract supplies 140–200 h but no route-stratified estimate or full PEG dose table. Single-dose/infusion pharmaceutical study, not community physique use.

Cycles people discuss

PEG-specific cycles	No PEG-IGF-1 on/off course or receptor-reset interval is established. Training blocks and equal-or-longer breaks are borrowed ideas.
Other-compound calendars	3–4 weeks of LR3 and 4–6 or 4–8 weeks of PEG-MGF concern different compounds. Proposed alternating PEG-MGF/GH/LR3 blocks do not supply a PEG-IGF cycle.

Notes

No PEG-IGF-1-specific on/off cycle is established. Training-block or bulk use and equal-or-longer breaks are borrowed ideas. Receptor-desensitization talk is a rationale people circulate, not evidence of a reset interval in PEG-IGF users.

3–4 weeks LR3; 4–6 or 4–8 weeks PEG-MGF. These preserved comparisons concern other compounds. An Eroids discussion proposes alternating 3–4-week PEG-MGF and GH/LR3 blocks; it supplies no PEG-IGF-1 cycle. Igf1-LR3 or MGF+MGF-PEG? (Community opinion · Accessed 2026-09-30)

Source context — Igf1-LR3 or MGF+MGF-PEG?: Three-to-four-week alternation concerns PEG-MGF then GH/LR3. This is advice/opinion, not a completed PEG-IGF course; necessity of GH supplementation is not adopted. Commercial forum and promotion badges visible.

Stacks

IGF and GH-axis combinations	Saved talk includes PEG-MGF, LR3/DES, HGH, CJC-1295/ipamorelin and MK-677. Name confusion and multiple agents prevent identifying what caused an effect.
Insulin, steroids and recovery peptides	Broader IGF-family stacks include insulin, anabolic steroids and BPC-157/TB-500. These are sparse or loosely identified combinations, not proven compatibility or synergy.

Notes

A stack can hide both benefit and harm. The record includes LR3/DES, PEG-MGF, HGH, CJC-1295/Ipamorelin, MK-677, insulin, steroids and recovery-peptide combinations. They obscure attribution and add unknowns. An unverified label also leaves identity, actual amount and purity unresolved.

With IGF-1 LR3: Dual “long PEG + daily LR3” logs exist in sparse form; high confound, high mislabel risk, and stacked hypo/growth-pathway load. [community]

With PEG-MGF: “Repair then growth” or “proliferation then differentiation” two-wave lore is usually told as PEG-MGF + LR3; some threads swap PEG-IGF-1 into that slot by name confusion. Timing stories (MGF early post-workout, longer IGF later) are lore, not controlled PEG-IGF-1 trials. [community]

With IGF-1 DES: DES as short local/post-workout spike vs longer systemic PEG — rare true dual logs; identity confusion remains. [community]

GH-axis (HGH, CJC-1295/Ipamorelin, MK-677): Layering exogenous IGF signaling on top of GH-raised endogenous IGF-1 is common stack talk; multi-agent attribution is weak and GH-feedback design claims from PEG-IGF-I do not make unsupervised polypharmacy “clean.” [community]

Insulin: Aggressive nutrient-partitioning stacks appear in broader IGF family talk; hypo risk compounds — especially relevant if someone is actually running LR3 or insulin while thinking they only have “mild PEG IGF.” [community]

AAS bulks: Growth-factor talk layered on steroid cycles; confounds dominate any size claim. [community]

BPC-157 / TB-500 (Wolverine-class recovery stacks): Injury-adjacent forums sometimes put growth factors near healing peptides; causality and product ID both muddy. [community]

Watch for

Low glucose and broader growth	The retained IGF-family cautions include low blood sugar, water retention and soft-tissue/cancer concerns. They are not PEG-specific event rates or proof of inevitable organ growth.
Serious symptoms	Native IGF-1 labeling warns about hypoglycemia, allergy, intracranial hypertension and neoplasia. That pediatric medicine is different, but a smoother-action claim cannot dismiss these concerns.
Unverified identity	Labels and stack packs may not establish molecule, actual amount or purity. A pump or fuller muscle cannot identify PEG-IGF-1 or prove new tissue growth.

Notes

Low blood sugar and growth outside muscle. The retained community cautions highlight insulin/LR3 combinations, fasting or carbohydrate restriction, water retention, abdominal or soft-tissue changes, and cancer concerns. These are broader IGF-family cautions, not PEG-specific event rates or proof of inevitable organ growth.

Severe headache, visual changes or allergic reactions matter. Native IGF-1 treatment labeling documents hypoglycemia, hypersensitivity, intracranial hypertension and neoplasia warnings. It concerns pediatric mecasermin, not PEG-IGF-1; those risks cannot be dismissed by a “smoother” marketing claim. INCRELEX (mecasermin) prescribing information (Official context · Accessed 2026-09-30)

Fullness cannot identify the molecule or prove growth. An IronMag PEG-MGF user described early fullness and later explicitly questioned whether it was new muscle. Similar sensations are easy to misassign to “PEG IGF.” PEG MGF users: fullness mistaken for growth (Personal report · Accessed 2026-09-30)

What not to assume: Vendor “PEG IGF stack packs” rarely prove molecular identity or ratio science — treat as marketing bundles. [community]

Source context — INCRELEX (mecasermin) prescribing information: Native rhIGF-1 in pediatric treatment, not PEG-IGF-1. Used only to explain adjacent risks; no label dose or adverse-event percentage transferred to PEG use.

Source context — PEG MGF users: fullness mistaken for growth: Other pages not read. PEG-MGF-only opening and later 200 mcg four-times-weekly fullness report are not PEG-IGF-1. Illustrates why similar feelings cannot identify a molecule or establish tissue growth.

Full notes

What PEG-IGF-1 actually is

PEG changes how the growth factor behaves. Attaching polyethylene glycol can slow removal and alter receptor and binding-protein interactions. IGF signaling affects many tissues, so “longer acting” does not mean muscle-selective. Official context
PEG-IGF-1, PEG-MGF and LR3 are separate identities. PEG-MGF is the MGF-related peptide discussed for repair; LR3 and DES are different IGF analogues. HGH and GH-releasing compounds act upstream. A vial labeled PEG-IGF cannot be assumed to match the pharmaceutical RO5046013 studied in humans. Community
Injectable discussion does not establish one common gym route. The preserved account includes SubQ (beneath skin) and IM (into muscle) talk. Clinical IV infusion is a separate research setting. There is no established oral, nasal or topical counterpart for these muscle goals in this record. Community

What people hope to get

Longer coverage and fewer injections. That is the attraction in the community account, alongside smoother recovery, muscle fullness and retaining size through hard training or cuts. These are discussion claims; stacks, diet and training make single-compound credit difficult. Community
Stamina and strength are claimed in a combination. An Eroids participant favored PEG-IGF with PEG-MGF and described post-workout use; increased stamina/strength before training was a prediction, without an isolated outcome log. Eroids

Doses discussed

No established PEG-IGF-1 community amount. The retained discussion has no stable construct-specific dose. Weekly or a few-times-weekly exposure is an intermittent-use idea, without a consistent matched amount, route and frequency. Community
20–50 or 20–100 mcg are borrowed IGF/LR3 comparisons. These overlapping chart bands are not verified PEG-IGF-1 amounts. The original does not establish whether they mean per injection or daily total for a PEG product; LR3's 5–7-times-weekly habit cannot resolve that gap. Community
100–400 mcg, 2–3 times weekly refers to PEG-MGF. That separate chart comparison stays separate from PEG-IGF-1. Neither its amount nor its frequency supplies a PEG-IGF schedule. Community

Half-life

Multi-day exposure is discussed; a community measurement is missing. AnabolicMinds debated whether days of systemic PEG-IGF activity were desirable. This was opinion about exposure, not a measured human half-life. AnabolicMinds
20–30 hours for LR3; 48–72 hours for PEG-MGF. These are distinct estimates repeated in the preserved comparison discussion, not PEG-IGF-1 values or established human measurements. The pharmaceutical PEG-IGF-I figure appears separately below. Community

Onset and how it may feel

A reliable first-dose onset is unknown. The community record describes no stimulant-like rush, possible site awareness, and mild fullness or recovery impressions during days 1–7. Those impressions lack a timed, verified PEG-IGF-only log. Community
Weeks 1–2 and 3–4 are observation windows. The original mentions checking pumps and recovery in the first two weeks and possible physique impressions around weeks 3–4. These are loosely attributed checkpoints, not demonstrated onset times or promised changes. Community

Duration of effects

Single-dose felt duration and offset are unknown. Multi-day circulation lore does not tell us how long a workout, fullness or recovery feeling lasts. The original's weeks 4–8 discussion describes extended runs; it does not measure one injection's effects. Community
Stopping is not a proven washout date. Residual-exposure discussion and post-stop impressions remain uncertain. Ongoing training and other compounds prevent a clean attribution of effects after the last reported administration. Community

Cycles and breaks

No PEG-IGF-1-specific on/off cycle is established. Training-block or bulk use and equal-or-longer breaks are borrowed ideas. Receptor-desensitization talk is a rationale people circulate, not evidence of a reset interval in PEG-IGF users. Community
3–4 weeks LR3; 4–6 or 4–8 weeks PEG-MGF. These preserved comparisons concern other compounds. An Eroids discussion proposes alternating 3–4-week PEG-MGF and GH/LR3 blocks; it supplies no PEG-IGF-1 cycle. Community Eroids

Watch for

Low blood sugar and growth outside muscle. The retained community cautions highlight insulin/LR3 combinations, fasting or carbohydrate restriction, water retention, abdominal or soft-tissue changes, and cancer concerns. These are broader IGF-family cautions, not PEG-specific event rates or proof of inevitable organ growth. Community
Severe headache, visual changes or allergic reactions matter. Native IGF-1 treatment labeling documents hypoglycemia, hypersensitivity, intracranial hypertension and neoplasia warnings. It concerns pediatric mecasermin, not PEG-IGF-1; those risks cannot be dismissed by a “smoother” marketing claim. Official context
A stack can hide both benefit and harm. The record includes LR3/DES, PEG-MGF, HGH, CJC-1295/Ipamorelin, MK-677, insulin, steroids and recovery-peptide combinations. They obscure attribution and add unknowns. An unverified label also leaves identity, actual amount and purity unresolved. Community

Separate research context

140–200 hours: pharmaceutical RO5046013. The 62-volunteer study used single SubQ administration or a 48-hour IV infusion; its abstract does not split half-life by route. No hypoglycemia occurred, and SubQ redness was the most frequent adverse event. The comparator was unmodified rhIGF-I. These findings do not establish a gym dose or felt duration. Official context
Mouse muscle repair depended on local delivery. After myotoxic injury, local IM PEG-IGF-I improved muscle-force and fibre-size measurements; systemic delivery did not help in that experiment. These are injured-mouse endpoints, not human recovery percentages. Animal context

What the community comparisons reveal

The positive PEG-IGF mention lacks a solo follow-up. HydeMind's combination appraisal is worth retaining, but its workout timing does not establish when PEG-IGF starts or stops working. Eroids
Longer exposure is also a concern. AnabolicMinds participants worried about systemic PEG-IGF reaching non-muscle tissue. Their warnings were speculative, not firsthand measured organ-growth reports. AnabolicMinds
Recovery praise and disappointment often concern PEG-MGF. In SteroidFreaks, one participant recalled little benefit from PEG-MGF/IGF; another praised PEG-MGF recovery while doubting new tissue growth. Neither reported PEG-IGF-1. SteroidFreaks
Fullness cannot identify the molecule or prove growth. An IronMag PEG-MGF user described early fullness and later explicitly questioned whether it was new muscle. Similar sensations are easy to misassign to “PEG IGF.” Personal report
Confident user guides still disagree. A Reddit LR3/DES/PEG-MGF guide prompted opposing efficacy claims and complaints about finding convincing logs. That debate adds practical skepticism, not a PEG-IGF outcome database. Reddit r/Peptides